A detailed history of Royal Bank Of Canada transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 7,680 shares of TERN stock, worth $44,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,680
Previous 7,861 2.3%
Holding current value
$44,160
Previous $53,000 20.75%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.49 - $10.8 $1,174 - $1,954
-181 Reduced 2.3%
7,680 $64,000
Q2 2024

Aug 14, 2024

BUY
$4.54 - $8.2 $19,426 - $35,087
4,279 Added 119.46%
7,861 $53,000
Q1 2024

Nov 05, 2024

SELL
$4.86 - $8.19 $20,795 - $35,045
-4,279 Reduced 54.43%
3,582 $23,000
Q1 2024

May 15, 2024

SELL
$4.86 - $8.19 $52,779 - $88,943
-10,860 Reduced 75.2%
3,582 $23,000
Q4 2023

Feb 14, 2024

SELL
$3.37 - $6.86 $90,140 - $183,491
-26,748 Reduced 64.94%
14,442 $93,000
Q3 2023

Nov 14, 2023

SELL
$4.7 - $8.55 $205,808 - $374,395
-43,789 Reduced 51.53%
41,190 $207,000
Q2 2023

Aug 14, 2023

BUY
$7.35 - $13.29 $257,066 - $464,817
34,975 Added 69.94%
84,979 $743,000
Q1 2023

May 15, 2023

BUY
$7.91 - $12.0 $394,092 - $597,864
49,822 Added 27374.73%
50,004 $592,000
Q4 2022

Feb 14, 2023

BUY
$4.62 - $10.18 $840 - $1,852
182 New
182 $1,000
Q2 2022

Aug 15, 2022

SELL
$1.5 - $3.0 $1,264 - $2,529
-843 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.83 - $6.7 $6,313 - $14,947
-2,231 Reduced 72.58%
843 $3,000
Q4 2021

Feb 14, 2022

BUY
$5.65 - $10.73 $7,474 - $14,195
1,323 Added 75.56%
3,074 $22,000
Q3 2021

Nov 15, 2021

BUY
$7.22 - $13.46 $8,339 - $15,546
1,155 Added 193.79%
1,751 $18,000
Q2 2021

Aug 16, 2021

BUY
$12.26 - $22.0 $7,306 - $13,112
596 New
596 $7,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $216M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.